Veridien Corporation (fka VRDE)

[ProfitScout]

Veridien Corporation Receives EPA Label Approval For Hepatitis A, B and C Kill Claims on Disinfectant Towelettes

ST. PETERSBURG, Fla., Oct 27, 2005 (BUSINESS WIRE) -- Veridien Corporation ( VRDE ):

-- The Patented Viraguard(R) Formula is the Only EPA Approved Disinfectant With Hepatitis A, B and C Label Claims That Is Also Drug Listed By the FDA As A Hand Antiseptic;

-- CDC estimates that 4.95 million Americans suffer from chronic hepatitis infections

Veridien Corporation ( VRDE ) announced today that the Viraguard(R) Hospital Hard Surface Disinfectant Towelettes have received stamped EPA approval for killing Hepatitis A, B and C viruses. These approvals now clearly distinguish the Viraguard(R) Disinfectant Towelettes as one of the premiere disinfecting wipes in the healthcare industry. Only Viraguard(R) Disinfectant Towelettes are authorized to make label claims about its effectiveness against all three Hepatitis viruses (A, B and C). The patented Viraguard(R) formula is the only EPA approved disinfectant with Hepatitis A, B and C label claims that is also drug listed by the FDA as a hand antiseptic.

According to the US Centers for Disease Control ("CDC"), the average rate of infections annually for hepatitis A, B and C is over 160,000 cases per year. As well, the CDC estimates that the number of Americans with chronic hepatitis infections exceeds 4.95 million people. ( www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm)

In addition to the Hepatitis A, B and C kill claims, the Viraguard(R) Disinfectant Towelettes now carry all the viral and bacterial kill claims of the Viraguard(R) liquid disinfectants, including Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-resistant Enterococcus Faecalis (VRE), Herpes Simplex-type 1 and 2, Escheria coli (E.coli) strain 157, Mycobacterium bovis (BCG, TB surrogate), Pseudomonas aeruginosa, Streptococcus Pyogenes, Salmonella choleraesius, Staphylococcus aureus, Respiratory syncytial virus (RSV), Rotavirus (SA-11 Group A), Influenza Hong Kong type 1 and 2, HIV-1 (aids virus), Trichophyton mentagrophytes (athlete's foot fungus), Cytomegalovirus (CMV) and Adenovirus Type 2.

Paul Dunnigan, VP-Marketing Group, "This is outstanding news for our healthcare, industrial and retail clientele. With the new EPA approved label claims, Viraguard(R) Infection Control Products provide our customers with the full Hepatitis and anti-viral protection they need in surface disinfecting wipes as well as in liquid disinfectants. We offer them equal protection for hand sanitizing by using the same tested, safe and effective formula in our hand antiseptic products. In particular, Veridien's products are critical in helping to control orally transmitted pathogens (Hepatitis A) and blood-borne pathogens (Hepatitis C) that threaten food workers, emergency medical workers, clinicians and physicians worldwide. Veridien's strategic multi-national client and distributors regard the anti-viral kill claims as a distinct advantage to leverage large contracts in the health and safety industry."

Jeff Selph, Chief Scientific Officer of Veridien, said, "We live in a highly infected world. Numerous outbreaks of Hepatitis and other viruses are driving the need for products with superior kill claims. Healthcare and industrial professionals can depend on Viraguard(R) Infection Control Products to help minimize many of the risks."

Viraguard(R) Infection Control products are available to healthcare practitioners and industrial materials managers through major distributors across the United States. Viraguard(R) Products can also be purchased for use at home or at the office at www.buyveridien.com.

For more information about Veridien Corporation, A Life Sciences Company, its products and investments in future technology, go to:

http://www.veridien.com

and

http://www.mycosol.com

Special Note: Forward-looking statements in this press release (identifiable by such words as "believes","expects") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes, and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.

SOURCE: Veridien Corporation

Veridien Corporation, Pinellas Park
Cheryl Ballou, 727-576-1600
[e-mail]


Copyright Business Wire 2005